Agentix Corp. (AGTX)
Oxford Ledge is still expanding full research coverage of AGTX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Agentix develops peripherally-restricted drug candidates to treat metabolic diseases like obesity and diabetes.
SEC filings
- 10-K Annual financial report with audited statements 2026-07-01
- 10-Q Quarterly financial report (unaudited) 2026-02-17
- 10-Q Quarterly financial report (unaudited) 2025-11-20
- 10-Q Quarterly financial report (unaudited) 2025-08-22
- 10-K Annual financial report with audited statements 2025-07-16
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for AGTX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open AGTX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.